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A B S T R A C T
Obesity is a chronic disease of multifactorial origin arising from
a long-term energy imbalance, in which both genetic and environ-
mental factors may be involved. Obesity is an important cause of
morbidity and mortality in developed countries. Implementation of
effective strategies in prevention and management of obesity
should become a major target in the health care systems world-
wide. Weight loss and maintenance depend on the interaction of
genetic, metabolic, psychobehavioral and environmental factors.
Responsiveness to weight reduction programmes shows a wide
interindividual variation and reliable weight loss predictors have
not been available.
Major advances have been made recently in the study of genetics
of obesity with more than 400 candidate obesity genes being char-
acterized. This paper summarizes available data on the involvement
of hereditary factors in weight loss and maintenance. Twin and fam-
ily studies demonstrated that the weight loss is strongly controlled
by genotype. Polymorphisms in several obesity candidate genes
was shown to influence the outcome of weight management. How-
ever, several studies yield ambiguous results. It should considered
that the eating behaviour as a major predictor of weight loss mainte-
nance is also significantly genetically determined.
Weight loss achieved in response to obesity treatment might also
be influenced by changes in obesogenic and/or leptogenic genes
expression induced by environmental factors such as the type of
ingested nutrient and level of physical activity.
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More comprehensive studies on interaction between candidate
obesity genes, psychobehavioral factors and environmental fac-
tors are needed for better understanding the outcome of weight
management in our increasingly obesogenic environment.
Key words: obesity, weight loss, weight loss maintenance, obesi-
ty candidate genes, gene polymorphisms, gene expression, envi-
ronmental factors, psychobehavioral factors
S T R E S Z C Z E N I E
Otyłość jest przewlekłą chorobą, wynikającą z długotrwałej nadwyżki
w bilansie energetycznym, spowodowanej wieloma, różnorodnymi
czynnikami zarówno genetycznymi, jak i środowiskowymi. Otyłość
jest istotną przyczyną chorobowości i śmiertelności w krajach roz-
winiętych. Wprowadzenie skutecznych strategii prewencji oraz wal-
ki z otyłością powinno być głównym celem opieki zdrowotnej na
całym świecie. Utrata, a następnie utrzymanie odpowiedniej masy
ciała zależy od wielu, współdziałających ze sobą czynników gene-
tycznych, metabolicznych, psychobehawioralnych i środowisko-
wych. Odpowiedź na programy powodujące utratę masy ciała świad-
czy o dużej różnorodności poszczególnych jednostek. Natomiast
czynniki predysponujące do utraty masy ciała są nieznane.
Ostatnio nastąpił duży postęp w badaniu genetycznie uwarunko-
wanej otyłości. Opisano już ponad 400 genów kandydatów otyło-
ści. W niniejszym artykule zebrano dostępne dane na temat dzie-
dzicznych czynników wpływających na utratę i utrzymanie masy
ciała. W badaniu przeprowadzonym wśród bliźniaków i ich rodzin
udowodniono, że otyłość ściśle wiąże się z genotypem. Na wynik
postępowania zmniejszającego masę ciała wpływa polimorfizm
kilku genów kandydatów otyłości. Niestety w niektórych dotąd prze-
prowadzonych badaniach uzyskano dwuznaczne wyniki. Niewąt-
pliwie należy więcej uwagi poświęcić nawykowemu jedzeniu jako
głównemu czynnikowi, od którego zależy utrzymanie odpowied-
niej masy ciała po schudnięciu co jest także, nawet w znacznym
stopniu, uwarunkowane genetycznie.
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Osiągnięcie zmniejszenia masy ciała w czasie leczenia otyłości
zależy także od zmian w ekspresji genów powodujących otyłość
i leptynę indukowanej różnego rodzaju czynnikami środowisko-
wymi, takimi jak pożywienie oraz aktywność fizyczna.
Należy przeprowadzić bardziej wnikliwe badania zależności mię-
dzy genami, kandydatami otyłości oraz czynnikami psychobeha-
wioralnymi i środowiskowymi w celu lepszego zrozumienia uzy-
skiwanych wyników postępowania redukującego masę ciała
w coraz bardziej sprzyjającym otyłości otoczeniu.
Słowa kluczowe: otyłość, utrata masy ciała, utrzymanie odpowiedniej
masy ciała, geny kandydaci otyłości, polimorfizm genów, ekspresja
genów, czynniki środowiskowe, czynniki psychobehawioralne
Over the last decades, the obesity prevalence increased
significantly and is becoming a public health problem
worldwide in both industrialized and developing coun-
tries. In many European countries every fourth or fifth
adult is obese. Obesity is a chronic disease of multifac-
torial origin characterized by enlargement of adipose
tissue as a result of an energy surplus caused by a long-
term positive energy balance. It origins from the interac-
tion between the external and genetic factors.
Genetic factors versus environmental
factors
A question is frequently asked whether the dramatic
progression of the obesity epidemic over the last two
decades at the turn of the millennium is attributable to
genetic predisposition rather than to environmental fac-
tors. Since the human genome is unlikely to have un-
dergone important changes over the short period of
several decades, the sharp rise in the obesity preva-
lence cannot be explained by genetic factors.
The 20th century brought not only industrialization
and mechanization but also subsequent changes to
human lifestyles. The population eating habits have been
modified substantially in the countries with increasing
obesity prevalence rates. Consumption of fats and sim-
ple sugars is increasing while fibre consumption is de-
creasing. Humans in general, and obese persons in
particular, have limited ability to burn fats regardless of
their high intake and thus the excessive fat is deposited
in the adipose tissue practically without limitation.
Decreased physical activity as a result of low levels
of habitual physical activity are another factor implica-
ted in the energy imbalance and the resulting increased
prevalence of obesity. Lower physical activity can be
ascribed to changes in transport, communications and
leisure and to the use of sophisticated technologies and
computers both at work and at home. Sedentary work
often coupled with sedentary leisure-time activities such
as using computers and watching TV, has become
a serious public health problem in this regard.
The regulation of body weight and energy home-
ostasis is subject to complex regulatory mechanisms
that maintain balance between energy intake, energy
expenditure and energy stores. Genetic factors play
an important role in this regulation as well as in deve-
lopment of obesity as reported for both animal models
and studies on humans [1]. Based on the current know-
ledge of the pathogenesis of obesity, the level of invo-
lvement of genetic factors in the development of obe-
sity is estimated to be 40–70% [2]. The last edition of
the human obesity gene map of 2003 reported more
than 400 genes, markers and chromosomal regions to
be linked to obesity [3]. Genes influence the regulato-
ry mechanisms involved in control of food intake, per-
ception of hunger and satiety, food preference, food
ingestion, nutrient absorption and burning, energy
expenditure and nutrient deposition in energy stocks.
Monogenic and polygenic obesities
Recently, several genes could be identified whose
mutations led to rare monogenic forms of obesity in
humans [4]. Genes for leptin, leptin receptor, proopio-
melanocortin (POMC), melanocortin 4 receptor (MC4-
R), melanocortin 3 receptor (MC3-R) and the enzyme
prohormone convertase 1 (PC1) are among these ge-
nes [1]. Nevertheless, mutations of these genes, with
the exception of MC4-R, belong to the very rare patho-
genetic factors of obesity in humans [5].
The heredity of obesity is due chiefly to interaction of
multiple candidate genes found at different locations on the
gene map and is therefore polygenic in nature. Candidate
obesity genes either predispose to obesity (obesogenic
genes) or promote leanness (leptogenic genes). Genes
may interact with each other (gene-gene interactions) or
with various environmental factors (gene-environment inte-
ractions). Interactions between biological (genes, hormo-
nes and neurotransmitters etc.), psychobehavioral and envi-
ronmental factors affect body fat accumulation and fat di-
stribution as well as obesity related health risks (fig. 1). Such
interactions result in a wide range of body weight phenoty-
pes from morbid obesity to asthenic body habitus. In view
of this polygenic heredity model, an adequate quantifica-
tion of the involvement of heredity and various candidate
genes in obesity development is not feasible.
Association and binding studies indicate links be-
tween candidate obesity genes and body weight, body
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mass index (BMI), body fat distribution and other phe-
notypic characteristics of obesity including obesity re-
lated health risks [3].
Genetic factors affecting body weight loss
With the development of molecular genetics, research
currently focuses on the role of genetic factors in body
weight loss and maintenance. Studies carried out in mo-
nozygotic twins analyze interaction of genetic factors with
weight loss programmes. Several studies emphasized
the familial aggregation of ability to lose weight. The role
of parental obesity in this respect was frequently demon-
strated. Other studies dealed with effects of polymorphism
of some candidate obesity genes on body weight loss
and maintenance. Weight loss maintenance is influen-
ced mainly by psychobehavioral factors that are frequ-
ently genetically determined. Finally, many studies ana-
lyze the impact of a weight loss intervention (characteri-
zed by nutrient intake and type of physical activities) on
expression of candidate obesity genes. Variation in
expression of obesogenic and leptogenic genes with type
of dieting and physical activities may have an effect on
efficacy of a weight loss intervention.
Studies on weight loss in monozygotic
twins
Studies comparing monozygotic and dizygotic twins were
the first to found evidence of the influence of heredity on
body weight loss. A study of Stunkard et al. [6] in mono-
zygotic twins revealed genetic factors to be significantly
involved in determination of BMI. High correlation of BMI
was shown in monozygotic compared to dizygotic twins
regardless of whether or not they shared the same envi-
ronment since birth. A study of Bouchard et al. [7] was
focused on responsiveness to a negative energy balan-
ce as a result of enhanced physical activities. Weight loss
was similar in pairs of identical twins but differed signifi-
cantly between pairs. Our study [8] revealed significant
similarity in weight loss in response to a 1-month weight
reduction regimen with a very low energy Redita diet for
obese monozygotic twins. Although body weight reduc-
tion showed wide interindividual variation, ranging be-
tween 5.9 to 12.4 kg, it was similar in pairs of monozygo-
tic twins. Intrapair resemblance in fat loss was 17 times
as high as resemblence between pairs (fig. 2). Further
analysis of these data revealed a high intra-pair correla-
tion (0.77) for metabolic efficiency [9].
Family background of obesity, ability to
oxidize fat and weight loss
In our previous study [10], a high fasting respiratory qu-
otient (RQ) was observed during the treatment by very low
calorie diet (VLCD) in obese patients who regained weight
at two-year follow-up (“weight regainers”) and in those who
exhibited repeated cycles of weight loss with a subsequ-
ent weight regain (“weight cyclers”). On the other hand,
obese patients who succeeded to retain the weight loss
initially achieved by the VLCD at 2-year follow-up (“weight
losers”) or those who did not exhibit weight fluctuations
(“weight non-cyclers”) were characterized by a significan-
tly lower fasting RQ. A high fasting RQ during the VLCD
treatment, which reflects low fat oxidation, should be
Figure 1. Interactions between biological (genes, hormones and
neurotransmitters), psychobehavioral and environmental factors
affect body fat accumulation and fat distribution as well as obesity
related health risks
Figure 2. Study conducted in obese female monozygotic twins
revealed that intrapair resemblance in VLCD-induced fat loss was
17 times as high as resemblence between pairs
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therefore considered as predictor of body weight gain. Obe-
se subjects who reported parental obesity demonstrated
significantly higher fasting RQ than those who reported
normal weight in both parents (fig. 3). Differences in RQ
due to parental obesity remained statistically significant
even after adjustment for confounders as body mass in-
dex, weight, fat mass, waist circumference, gender, age,
average macronutrient intake during the week preceding
calorimetry and serum levels of insulin and C-peptide.
Obese subjects with both parents obese were found 3.3
times more frequently (42.8% vs. 12.9%) in a cohort in the
upper quintile of RQ (low fat oxidizers) than in a cohort in
the lower quintile of RQ (high fat oxidizers). In contrast,
obese individuals with normal weight parents were reve-
aled much more frequently in the lower quintile of RQ than
in the upper quintile of RQ (38.7% vs. 7.1%).
 It is evident that an ability to oxidize fat, which af-
fects the outcome of weight reduction programme, is
greatly influenced by family background of obesity. Not
only fasting RQ but also 24-hr RQ is controlled by fami-
lial factors. Toubro et al. [11] revealed that familial mem-
bership explained 27% of the variation in 24-hr RQ be-
tween individuals. According to Heitmann et al. [12]
a high intake of dietary fat is significantly associated with
weight gain only among women with parental history of
obesity. This susceptibility to weight gain after a high
consumption of fat in individuals with parental history of
obesity might be due to familial determination of ability
to oxidize fat both during fasting and after fat load.
Weight loss in monogenic forms of obesity
Since the monogenic forms of obesity are rather scar-
ce, only few reports on efficacy of the therapy have
been available. It can be expected that if the therapy of
obesity is targeted on correction of the disorder linked
to gene mutation, it should be successful. E.g. obesity
due to leptin gene mutation was successfully control-
led by administration of recombinant leptin both in
adults [13] and children [4]. In view of the known role
of genes in the pathogenesis of obesity, some physi-
cians may adopt a nihilist attitude to the treatment of
this disorder. Nevertheless, such an approach is unju-
stified as also shown by the last report on body weight,
body fat mass and insulin susceptibility normalization
following a 11-month comprehensive weight loss inte-
rvention in three children with R236G mutation in the
proopiomelanocortin gene [14]. The most common
monogenic form of human obesity is that caused by
mutations in the gene that encodes melanocortin 4 re-
ceptor (MC4-R) [15] and is associated with intensive
feeling of hunger and hyperphagia in childhood which
decreases with aging. No comprehensive clinical stu-
dies on weight loss in patients with MC4-R mutation
have been published. However, Butler and Cone [16]
described hyperphagia in MC4-R deficient mice fed with
a high-fat diet, whereas no hyperphagia was observed
when low-fat diet was introduced, thus indicating gene-
environment interaction and supporting the role of low-
fat diet in weight management even in genetically de-
termined obesities.
Polymorphisms of obesity candidate
genes and weight loss
Polymorphisms of several genes have been studied
with regard to weight loss and weight loss maintenan-
ce in common obesity which is characterized by poly-
genic heredity (tab. 1).
b3 adrenoreceptor (ADRb3) plays an important role
in adipocyte metabolism as a regulator of catechola-
mine-induced lipolysis. Among frequent polymorphi-
sms of the ADRb3 gene is Trp64Arg resulting from the
substitution of tryptophane with arginine at locus 64.
Some studies focused on the effect of the Trp64Arg
polymorphism of the ADRb3 gene on long-term weight
loss regimens. Yoshida et al. [17] found homozygotes
for the Arg64 allele to be less successful in reducing
weight than Trp64 carriers. Other Japanese studies [18,
19] also confirmed that women with Trp64Arg polymor-
phism tend to lose weight more slowly when enrolled
in a weight loss programme. Shimizu and Mori [20]
reported Trp64Arg polymorphism carriers to achieve
almost 50% lower weight loss compared to persons
with normal b3 adrenoreceptor alleles when given an
antiobesity drug mazindol while other studies [21–24]
Figure 3. Non-protein respiratory quotient (RQ) in obese subjects
categorized according to parental history of obesity (Hainer et al.
2000)
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found no difference in weight loss between persons
with various polymorphisms of the ADRb3 gene. Raw-
son et al. [24] did not reveal any difference in changes
to body composition and energy expenditure between
the Trp64Arg carriers and non-carriers following we-
ight loss. These discordances could be ascribed to lack
of homogeneity of the study groups (obese versus
nonobese subjects, diabetics versus nondiabetics) or
to ethnic differences. However, a study in Chinese chil-
dren aged 8–11 years reported a significant body we-
ight decrease in Trp64Arg polymorphism carriers as
well [25].
Another study dealt with the effect of the Trp64Arg
polymorphism on body fat distribution during weight
reduction [26]. Following a three-month weight reduc-
tion regimen, Arg64 carriers compared to Arg64 non-
carriers showed a lower ratio of visceral to subcutane-
ous fat, which was particularly true of postmenopausal
women. Tchernof et al. [22] and Kim et al. [23] repor-
ted visceral fat reduction to be lower in the Arg allele
carriers compared to non-carriers after intervention.
Benecke et al. [27] described synergism between the
b3 adrenoreceptor gene polymorphism (Trp64Arg) and
insulin receptor substrate (IRS-1) gene polymorphism
(Gly972Arg) in weight loss control. The coincidence of
these two polymorphisms was linked to lower weight
loss and higher incidence of type 2 diabetes in obese
women following a 13-week weight loss intervention.
A question remains unanswered whether the presence
of these polymorphisms is one of the major causes of
lower weight loss as observed in most diabetics on
a weight reduction regimen.
PPARg2 is an intracellular transcription factor that
plays a role in adipogenesis and glucose and lipid ho-
meostasis. A metaanalysis of Pro12Ala polymorphism
of the PPARg2 gene showed positive correlation with
BMI. Higher BMI scores were also found in Ala-carriers
compared to Ala-non-carriers in a ten-year follow-up
study and a three-year follow-up study [28, 29]. Vario-
us intervention studies were carried out to elucidate
the relationship between the PPARg2 genotype and
weight loss. Lindi et al. [29] reported patients with the
Ala12Ala allele to be more successful in reducing body
weight than patients with other genotypes. Neverthe-
less, the study of Nicklas et al. [30] did not find any
significant difference in weight loss between the two
groups. In our pilot study, we came to the same conc-
lusion [31]. A study of 108 patients followed up for four
years on average did not reveal any significant diffe-
rence in weight loss between carriers and non-carriers
of the Ala12 allele of the PPARg2 gene.
Uncoupling proteins (UCPs) are a family of trans-
membrane proteins located on the inner mitochondrial
membrane. Their function is to uncouple the ATP for-
mation from mitochondrial respiration which results in
increased heat formation and higher energy expendi-
ture. Uncoupling protein 1 (UCP1) whose main expres-
sion site is brown adipose tissue plays an important
role in thermogenesis. Uncoupling protein 2 (UCP2) is
similar in structure to uncoupling protein 3 (UCP3), but
unlike UCP3 found exclusively in skeletal muscle, it is
present in several tissues. Presumably uncoupling pro-
teins play an important role in energy metabolism sin-
ce they act as transmembrane transporters across the
inner mitochondrial membrane in cells. Some studies
pointed out correlations between certain UCP gene
polymorphisms and resting energy expenditure, phy-
sical activity efficacy, substrate oxidation, energy me-
tabolism, BMI, obesity and type 2 diabetes. The role of
the UCP1 gene polymorphism in weight loss was reve-
aled by Fumeron et al. [21]. They found the A-3826G
polymorphism of the UCP1 gene to be linked to lower
weight loss in response to a 25% reduction of energy
intake. Harper et al. [32] reported higher UCP3 mRNA
expression in persons responsive to dietary interven-
tion compared to those who were resistant to dietary
measures.
Leptin. Obese patients whose leptin gene is not
mutated often have high leptin levels that may indicate
leptin resistance. Leptin administration in these obese
patients usually does not promote weight loss. Leptin
gene polymorphism in the promotor region 5´ is
Table 1. Obesity candidate genes that influence weight loss in
weight management programmes
Gene Polymorphism
Leptin C-2549A (5´ region)
Leptin receptor Ser (T) 343 Ser (C)
Serotonin receptor –759 C/T
Neuromedin b P73T
PPARg2 Pro12Ala
ADRb3 Trp64Arg
UCPs UCP1 (A-3826G)
UCP3 promotor (–55C > T)
IRS-1 IRS-1 (Gly972Arg)
CYP 19 11-repeat allele
COMT Val/Val
PNMT G-148A
G protein b3 subunit C825T
PPARg2 — peroxisome proliferator-activated receptor g2; ADRb3 — b3-ad-
renergic receptor; UCPs — uncoupling proteins; IRS-1 — insulin recep-
tor substrate 1; COMT — catechol-ortho-methyltransferase; CYP 19  —
subclass 19 cytochrome P450 aromatase; PNMT — Phenylethanolamin
N-methyltransferase
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linked to lower weight loss in response to low-energy
diet [33]. A study focused on the search for weight loss
predictors revealed the baseline leptin level (adjusted
for age and sex) to be a suitable weight loss predictor
in a 2-year cognitive behavioral intervention for obese
men [34].
Leptin receptor. Scarce reports on the effect of the
leptin receptor gene polymorphism on weight loss in
obese persons have been published. Female carriers
of the C allele of the leptin receptor gene polymorphism
/Ser (T) 343 Ser (C)/ were shown to be more success-
ful in a dietary weight loss intervention [35].
Serotonin receptor. Serotonin is involved in food
intake regulation in the central nervous system (CNS)
by inducing satiety. The CNS serotonin receptors me-
diate the effects of serotonin on food intake control.
The -759 C/T polymorphism of the 5-HT2C serotonin
receptor is linked to lower weight loss in a weight re-
duction intervention for heterozygotes compared to
both of the homozygote types (CC and TT) [36]. Ano-
ther polymorphism in the gene of the same serotonin
receptor is linked to weight loss in adolescent females
and seems to be involved in the development of ano-
rexia nervosa [37].
CYP 19 (subclass 19 cytochrome P450 aromata-
se) and COMT (catechol-ortho-methyltransferase). The
concomitance of the defined polymorphisms in the
genes CYP19 (11-repeat allele) and COMT (Val/Val)
leads to more pronounced reduction in BMI and body
fat in response to a one-year regular exercise program
in overweight and obese postmenopausal women [38].
Genes affecting response to drug treatment of
obesity. As mentioned before, the carriers of Trp64Arg
polymorphism of b3 adrenoreceptor exhibited lower
weight loss in response to mazindol treatment [20].
Phenylethanolamine N-methyltransferase (PNMT) is
an enzyme which plays a major role in catecholamine
metabolism and catalyzes the conversion of noradre-
nalin to adrenalin. The G-148A polymorphism homo-
zygotes showed higher weight loss in a 3-month thera-
py with a weight loss drug sibutramine [39]. G-protein
b3 subunit C825T polymorphism influenced differen-
tly weight loss in placebo controls and study subjects
given a serotonin-noradrenalin reuptake inhibitor sibu-
tramine [40]. The placebo controls with the TT/TC ge-
notypes showed higher weight loss compared to tho-
se with the CC genotype. On the other hand, the indivi-
duals with the CC genotype achieved higher weight
loss in response to sibutramine administration compa-
red to those with the TT/TC genotypes. Studies on drug-
induced weight loss provide additional evidence that
genotyping could be of relevance in predicting effica-
cy of antiobesity drugs for obesity treatment.
Eating behaviour and weight loss
It is to be noted that weight loss maintenance clearly
depends on the psychobehavioral factors such as the
type of eating behaviour. In a recent study we found
that the weight loss in response to a one-year weight
loss programme including administration of the antio-
besity drug sibutramine is significantly associated with
decrease in disinhibition scores as assessed by the
Eating Inventory [41]. Disinhibition score is a charac-
teristic of the eating behaviour of a person prone to
non-compliance with a weight loss regimen and to ove-
reating in response to stress, job and family related
problems, increased alcohol intake and depression. Di-
sinhibition scores show a strong hereditary link (here-
dity rate of 40%) and the gene on chromosome 3, which
is most linked to disinhibition, also codes for PPARg
[42]. Based on the most recent study of Bouchard et
al. [43], a potential candidate gene determining disin-
hibition and hunger as eating behaviour factors is
a gene on chromosome 15 encoding the hormone neu-
romedin b, a member of the family of bombesin-like
peptides. Neuromedin b gene polymorphism (P73T
polymorphism T allele homozygote carriers) was lin-
ked not only to higher disinhibition and more hunger
but also to greater body fat accumulation in their
6-year follow-up study [43].
Effects of the environmental factors on
expression of candidate obesity genes
 Responsiveness to weight loss intervention may also
be modified by effects of environmental factors such
as the type of ingested food (e.g., type of nutrient and
its character) and level of physical activities on expres-
sion of obesogenic and leptogenic genes. Modern
molecular genetics provides the possibility to use the
microarray method to examine expression of multiple
genes in a single adipose tissue specimen. Lopéz et
al. [44] examined about 4500 genes in obese rats with
cafeteria-diet-induced obesity and their controls. The
cafeteria diet induced higher expression of genes in-
volved in fat metabolism regulation and adipocyte dif-
ferentiation. The highest expression was identified for
leptin (ob), PPARg 2 and FABP (Fatty Acid — Binding
Protein) genes. Olive oil administration increases
expression of thermogenic genes UCP1 and UCP2 in
brown adipose tissue and of UCP3 in muscle [45]. In-
take of oil with medium-chain triglycerides (MCT),
a class of fatty acids, leads to reduction of adipose mass
and lower expression of adipogenic genes PPARg and
C/EPB a in rats [46]. UCP1 expression in brown adipose
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tissue is stimulated by carotenoids ingested in foods
[47]. Nevertheless, our pilot study did not found signi-
ficant changes to the UCP2 gene expression in subcu-
taneous adipose tissue for obese women following vi-
tamin A administration [48]. Ribot et al. [49] presume
that vitamin A intake correlates with fat accumulation
and changes in PPARg expression. Experimental stu-
dies revealed that the type of diet could influence
expression of genes controlling food intake. High fat
diet decreases serotonin receptor gene expression in
the hypothalamus of rats [50].
 Expression of candidate obesity genes is influen-
ced not only by diet but also by physical activities [51].
Short-term physical training decreases PPARg gene
expression and at the same time increases gene
expression for multiple enzymes involved in fat trans-
port and oxidation in human skeletal muscle [52]. UCP3
expression in human skeletal muscle increases follo-
wing a single workout but is decreased by endurance
training [53].
 The fact that both weight loss and maintenance
are influenced not only by polymorphisms of candida-
te obesity genes but also by the level of their expres-
sion is suggestive of the need for a comprehensive
approach to the study of factors involved in weight loss
regulation in weight reduction regimens.
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